KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 105 filers reported holding KEROS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2,206,443 | +94.5% | 48,281 | +181.8% | 0.00% | – |
| Q1 2024 | $1,134,337 | +66.5% | 17,135 | 0.0% | 0.00% | – |
| Q4 2023 | $681,288 | +92.8% | 17,135 | +54.6% | 0.00% | – |
| Q3 2023 | $353,390 | -51.7% | 11,085 | -35.3% | 0.00% | – |
| Q2 2023 | $731,666 | 0.0% | 17,135 | 0.0% | 0.00% | – |
| Q1 2023 | $731,666 | -11.1% | 17,135 | 0.0% | 0.00% | – |
| Q4 2022 | $822,824 | -99.9% | 17,135 | 0.0% | 0.00% | – |
| Q3 2022 | $644,620,000 | +110.5% | 17,135 | +54.6% | 0.00% | – |
| Q2 2022 | $306,279,000 | -29.7% | 11,085 | +38.4% | 0.00% | – |
| Q1 2022 | $435,584,000 | -7.1% | 8,010 | 0.0% | 0.00% | – |
| Q4 2021 | $468,665,000 | +8.8% | 8,010 | +14.4% | 0.00% | – |
| Q1 2021 | $430,850,000 | +0.1% | 7,000 | +14.8% | 0.00% | – |
| Q4 2020 | $430,294,000 | – | 6,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 292,833 | $17,134,000 | 5.65% |
| Deep Track Capital, LP | 1,300,000 | $76,063,000 | 5.37% |
| Octagon Capital Advisors LP | 340,214 | $19,906,000 | 3.87% |
| Opaleye Management Inc. | 265,750 | $15,549,000 | 3.30% |
| First Light Asset Management, LLC | 552,098 | $32,303,000 | 2.31% |
| Altium Capital Management LP | 116,000 | $6,787,000 | 1.87% |
| Nantahala Capital Management | 796,698 | $46,615,000 | 1.64% |
| Orbimed Advisors | 1,679,417 | $98,263,000 | 1.26% |
| Darwin Global Management, Ltd. | 111,500 | $6,524,000 | 1.00% |
| Parkman Healthcare Partners LLC | 69,861 | $4,088,000 | 0.90% |